0001193125-26-099434
SEC filingImageneBio Inc reported a net loss of $45.3 million for fiscal year 2025, with minimal revenue of $800,000 from license agreements. The company incurred significant operating expenses totaling $49.3 million, primarily driven by research and development costs of $28.5 million and general and administrative expenses of $20.7 million. Despite the operating loss of $48.5 million, the company generated $2.8 million in other income, primarily from interest income. The balance sheet shows strong liquidity with $94.5 million in cash and cash equivalents and $40.8 million in marketable securities, resulting in total current assets of $140.3 million. The company's cash position improved significantly with a net increase of $82.4 million in cash and cash equivalents, largely due to $135.5 million in net cash provided by financing activities including PIPE financing and term loan proceeds. The company's accumulated deficit stands at $230.1 million, reflecting its development-stage status.
ImageneBio Inc reported a net loss of $45.3 million for fiscal year 2025, with minimal revenue of $800,000 from license agreements. The company's operating loss was $48.5 million, driven by total operating expenses of $49.3 million. Research and development expenses accounted for $28.5 million, while general and administrative expenses totaled $20.7 million. The company generated $2.8 million in other income, primarily from interest income of $2.0 million and other income of $717,000. After accounting for income tax provision of $350,000 and accretion of redeemable convertible preferred shares of $7.0 million, the net loss available to common stockholders was $52.4 million. The company reported a net loss per share of $10.00 for both basic and diluted calculations, based on weighted-average common shares outstanding of 4.9 million.
The company generated $800,000 in license revenue during fiscal year 2025. No segment breakdown or geographic mix information was provided in the available data. The revenue appears to be minimal relative to the company's operating expenses, indicating that ImageneBio remains in a development stage with limited commercial operations. No additional revenue sources or growth drivers were disclosed in the provided financial data.
Given the minimal revenue of $800,000 and significant operating expenses of $49.3 million, the company operates at a substantial loss. The operating loss margin cannot be meaningfully calculated due to the minimal revenue base. The cost structure is dominated by research and development expenses of $28.5 million and general and administrative expenses of $20.7 million. The company's net loss margin relative to its minimal revenue is extremely high, reflecting its pre-revenue development stage status.
The company used $47.8 million in net cash from operating activities during fiscal year 2025. Investing activities used $5.8 million in net cash, primarily from purchases of marketable securities. Financing activities provided $135.5 million in net cash, including proceeds from term loan of $15.0 million and proceeds from common stock issued in PIPE Financing of $71.1 million. The balance sheet shows strong liquidity with $94.5 million in cash and cash equivalents and $40.8 million in marketable securities. Total current assets stand at $140.3 million, while total current liabilities are $11.2 million. The company has total assets of $153.0 million and total liabilities of $19.8 million. Stockholders' equity shows a deficit of $133.1 million, with accumulated deficit of $230.1 million.
No specific management guidance, strategic priorities, or forward-looking statements were provided in the available financial data. The company's significant cash position of $94.5 million provides runway for continued operations, but the substantial operating losses and minimal revenue indicate ongoing development activities. The company's financial position reflects its status as a development-stage biotechnology company with significant research and development investments.